PMC Articles for MedGen (Select 1715782) - PMC

Result Filters

Links from MedGen

Items: 1 to 20 of 192

<< First< Prev

Page of 10

Select item 110070191.

Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS‐mediated mechanisms

Xining Zhang, Xingming Liao, Min Wang, Jiao Liu, Jiaxin Han, Dong An, Tiezheng Zheng, Xuefei Wang, Hailing Cheng, Pixu Liu

Cancer Sci. 2024 Apr; 115(4): 1170–1183. Published online 2024 Jan 29. doi: 10.1111/cas.16085

PMCID:: PMC11007019

Abstract Article PDF–41M

Select item 109817522.

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Elena Giudice, Tzu-Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, Nahoko Sato, Jane B. Trepel, Jung-Min Lee

Nat Commun. 2024; 15: 2805. Published online 2024 Mar 30. doi: 10.1038/s41467-024-47215-6

PMCID:: PMC10981752

Abstract Article PDF–3.7M

Select item 109512113.

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain McNeish, Rosalind Glasspool, Marcia Hall, Rene Roux, Agnieszka Michael, Andrew Clamp, Gordon Jayson, Rebecca Kristeleit, Susana Banerjee, Anita Mansouri

Br J Cancer. 2024 Apr 6; 130(6): 941–950. Published online 2024 Jan 20. doi: 10.1038/s41416-023-02567-6

PMCID:: PMC10951211

Abstract Article PDF–675K

Select item 109366594.

TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation

Kaiwen Zhang, Xingyu Zheng, Yiqing Sun, Xinyu Feng, Xirong Wu, Wenlu Liu, Chao Gao, Ye Yan, Wenyan Tian, Yingmei Wang

Cancer Biol Ther. 2024; 25(1): 2325126. Published online 2024 Mar 6. doi: 10.1080/15384047.2024.2325126

PMCID:: PMC10936659

Abstract Article PDF–7.9M

Select item 109306235.

MiR-1-3p通过靶向FZD7增强卵巢癌细胞对铁死亡的敏感性

章迪, 屈斌, 胡彬, 曹可欣, 沈浩明

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Nov 28; 47(11): 1512–1521. Chinese. doi: 10.11817/j.issn.1672-7347.2022.210800

PMCID:: PMC10930623

Abstract Article PDF–1.9M

Select item 109055526.

BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer

Caroline Stahnke Richau, Nicole de Miranda Scherer, Bruna Palma Matta, Elvismary Molina de Armas, Fábio Carvalho de Barros Moreira, Anke Bergmann, Claudia Bessa Pereira Chaves, Mariana Boroni, Anna Claudia Evangelista dos Santos, Miguel Angelo Martins Moreira

Cancer Med. 2024 Feb; 13(3): e6729. Published online 2024 Feb 2. doi: 10.1002/cam4.6729

PMCID:: PMC10905552

Abstract Article PDF–1.0M

Select item 108781497.

A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer

Tianqing Yan, Xiaolu Ma, Kaixia Zhou, Jiazhen Cao, Yanan Tian, Hui Zheng, Ying Tong, Suhong Xie, Yanchun Wang, Lin Guo, Renquan Lu

Int J Biol Sci. 2024; 20(4): 1279–1296. Published online 2024 Jan 27. doi: 10.7150/ijbs.89700

PMCID:: PMC10878149

Abstract Article PDF–9.5M

Select item 108704618.

Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target

Wei Li, Limei Huang, Nana Qi, Qinle Zhang, Zailong Qin

BMC Genomics. 2024; 25: 183. Published online 2024 Feb 16. doi: 10.1186/s12864-024-10056-0

PMCID:: PMC10870461

Abstract Article PDF–8.4M

Select item 108458109.

CD47—a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features

Xukai Luo, Jiahang Mo, Min Zhang, Wu Huang, Yiting Bao, Ruoyao Zou, Liangqing Yao, Lei Yuan

World J Surg Oncol. 2024; 22: 44. Published online 2024 Feb 6. doi: 10.1186/s12957-024-03308-6

PMCID:: PMC10845810

Abstract Article PDF–2.6M

Select item 1079942710.

CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

Yunshu Zhu, Leilei Liang, Yuxi Zhao, Jian Li, Jia Zeng, Yihang Yuan, Ning Li, Lingying Wu

J Nanobiotechnology. 2024; 22: 35. Published online 2024 Jan 19. doi: 10.1186/s12951-024-02295-w

PMCID:: PMC10799427

Abstract Article PDF–6.6M

Select item 1077095611.

N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation

Han Li, Run Lin, Yanna Zhang, Yanni Zhu, Shuting Huang, Jing Lan, Nian Lu, Chuanmiao Xie, Shanyang He, Weijing Zhang

Mol Cancer. 2024; 23: 5. Published online 2024 Jan 6. doi: 10.1186/s12943-023-01917-5

PMCID:: PMC10770956

Abstract Article PDF–13M

Select item 1073200212.

Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer

Ferdynand J. Kos, Paul Frankel, Mihaela Cristea, Melissa Eng, Raechelle Tinsley, Shannon Dempsey, Nora Ruel, Daphne Stewart, Thanh H. Dellinger, Don J. Diamond

Cancer Res Commun. 2023 Dec; 3(12): 2585–2595. Published online 2023 Dec 20. doi: 10.1158/2767-9764.CRC-23-0394

PMCID:: PMC10732002

Abstract Article PDF–5.6M

Select item 1072938913.

Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer

Mengjun Zhang, Jialin Wang, Yan Guo, Haodi Yue, Lindong Zhang

J Ovarian Res. 2023; 16: 240. Published online 2023 Dec 19. doi: 10.1186/s13048-023-01314-y

PMCID:: PMC10729389

Abstract Article PDF–10M

Select item 1067367714.

A Phase 2 Study of Prexasertib (LY2606368) in Platinum Resistant or Refractory Recurrent Ovarian Cancer

Panagiotis A. Konstantinopoulos, Jung-min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer

Gynecol Oncol. Author manuscript; available in PMC 2023 Nov 24.

Published in final edited form as: Gynecol Oncol. 2022 Nov; 167(2): 213–225. Published online 2022 Sep 30. doi: 10.1016/j.ygyno.2022.09.019

PMCID:: PMC10673677

Abstract Article PDF–1.4M

Select item 1066242015.

The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer

Melayshia McFadden, Santosh Kumar Singh, Briana Kinnel, Sooryanarayana Varambally, Rajesh Singh

J Ovarian Res. 2023; 16: 220. Published online 2023 Nov 21. doi: 10.1186/s13048-023-01308-w

PMCID:: PMC10662420

Abstract Article PDF–1.9M

Select item 1064559116.

Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer

Attila Szénási, Enakshi Sivasudhan, Hong Du, Peizhuo Zhang, Jie Huang, Zhijun Zhang, Sonia Rocha, Mu Wang

Cancer Gene Ther. 2023; 30(11): 1554–1568. Published online 2023 Aug 15. doi: 10.1038/s41417-023-00659-2

PMCID:: PMC10645591

Abstract Article PDF–4.6M

Select item 1061406717.

Clinicopathological and Prognostic Values of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Ovarian Clear Cell Carcinoma for Predicting Tumor Recurrence, Platinum Resistance and Survival

HYUNWOO YOO, HYUN-SOO KIM

Cancer Genomics Proteomics. 2023 Nov-Dec; 20(6): 626–636. Published online 2023 Nov 3. doi: 10.21873/cgp.20411

PMCID:: PMC10614067

Abstract Article PDF–4.9M

Select item 1051197218.

Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes

Zena Alizzi, Sayeh Saravi, Saira Khalique, Thirza McDonald, Emmanouil Karteris, Marcia Hall

Int J Gynecol Cancer. 2023 Sep; 33(9): 1427–1433. Published online 2023 Aug 4. doi: 10.1136/ijgc-2023-004483

PMCID:: PMC10511972

Abstract Article PDF–946K

Select item 1049938219.

Therapeutic strategies targeting folate receptor α for ovarian cancer

Jia Mai, Limei Wu, Ling Yang, Ting Sun, Xiaojuan Liu, Rutie Yin, Yongmei Jiang, Jinke Li, Qintong Li

Front Immunol. 2023; 14: 1254532. Published online 2023 Aug 30. doi: 10.3389/fimmu.2023.1254532

Correction in:: Front Immunol. 2024; 15: 1403324.

PMCID:: PMC10499382

Abstract Article PDF–1.4M

Select item 1046299920.

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report

Fiamma Buttitta, Pietro Di Marino, Lara Felicioni, Francesca Chiara Primavera, Benedetta Ferro, Claudia Zampacorta, Maria Paola Pasciuto, Rebecca Rossetti, Marianna Tudini, Antonio Marchetti, Emanuela D’Angelo

Pathologica. 2023 Apr; 115(2): 107–110. Published online 2023 Apr 30. doi: 10.32074/1591-951X-871